Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	Blinded Phase: SIM 200 mg
Total, all-cause mortality	Blinded Phase: SIM 700 mg
Total, all-cause mortality	Blinded Phase: Placebo
Total, all-cause mortality	Open-Label Phase: SIM 700 mg
Total, other adverse events	Blinded Phase: SIM 200 mg	85	87
Total, other adverse events	Blinded Phase: SIM 700 mg	81	86
Total, other adverse events	Blinded Phase: Placebo	83	85
Total, other adverse events	Open-Label Phase: SIM 700 mg	32	40
Total, serious adverse events	Blinded Phase: SIM 200 mg	37	87
Total, serious adverse events	Blinded Phase: SIM 700 mg	36	86
Total, serious adverse events	Blinded Phase: Placebo	25	85
Total, serious adverse events	Open-Label Phase: SIM 700 mg	17	40

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01672879/event-totals